TMEM97 and cancer: McCurdy and co-workers carried out extensive researchon developing selective σ2R probes to elucidate thereceptor’s functional roles in several medical conditions,including cancer.51,55,138112,166,167 Notably,in 2015, Nicholson et al. reported the pharmacological characterizationof a σ2R-preferred ligand bearing the N-(4-fluorophenyl)piperazine as a cyclic amine moiety (CM572, Figure 24).166 This new compound was initially developed withina set of isothiocyanate analogs of SN79 (Figure 24), a well-characterized mixed σ1R/σ2R antagonist (σ1Ki = 27 nM, and σ2Ki = 7 nM).